allo-revcar01-t
Cell therapyexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2023 (NCT05949125)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Interleukin-3 receptor subunit alphaImmunity, passive
IL3RA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05949125 | Phase 1 | Aug 31, 2023 | Allucent, AvenCell |
Showing 1 of 1 trials
Page 1 / 1